
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is poised for long-term success due to its strong pipeline and commercial execution with its groundbreaking ImmTAX platform. The company's main product, KIMMTRAK, is already achieving significant sales and market penetration in the treatment of mUM, and its other drug candidates show promising potential in treating various oncology, infectious, and autoimmune diseases. The recent data presented by the company at various healthcare conferences further solidifies the efficacy of KIMMTRAK and its potential for continued success. These factors, paired with the company's strong financials and continued growth, make it a promising investment opportunity.
Bears say
Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of drug candidates in multiple therapeutic areas. However, their main product, KIMMTRAK, is the only product generating revenue and has limited potential in treating a specific type of cancer. With no guarantee of success for their other early-stage programs, regulatory and clinical risks, and a high potential for dilution, the company may struggle to achieve their ambitious $75 price target. Additionally, their use of varying exchange rates makes their financials appear inconsistent and unreliable.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares